Charity angry at NICE decision on Xolair – OnMedica


Daily Mail

Charity angry at NICE decision on Xolair
OnMedica
Omalizumab is licensed as add-on therapy for adults and children aged at least 6 years, who have severe persistent allergic asthma and meet other criteria.
Asthma drug denied to young childrenExaminer.com
UK's NICE reaffirms decision to deny use of Novartis' asthma drug Xolair for The Pharma Letter
Under-12s to be denied asthma jab only if they live in EnglandDaily Mail
Telegraph.co.uk –Healthcare Republic –Nursing Times
all 16 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *